Shared on10 Aug 25Fair value Decreased 9.63%
Despite a notable improvement in both future P/E and net profit margin, Intellia Therapeutics’ consensus analyst price target has been revised downward from $37.11 to $35.23. What's in the News Phase 3 HAELO trial for lonvo-z in hereditary angioedema (HAE) is ongoing, showing strong interim efficacy data; drug has received multiple regulatory designations, including FDA Orphan Drug and RMAT.
Shared on24 Apr 25Fair value Decreased 2.75%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.088%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 105.7x to 117.8x.
Shared on09 Apr 25Fair value Decreased 7.87%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.